Inflammatory bowel disease and pregnancy: Report of two cases treated with infliximab and a review of the literature

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 10, 2010, Pages 1260-1264

  Correia, Lucianna Motta ^a   Bonilha, Danielle Queiroz ^a   Ramos, Juliana Dantas ^a   Ambrogini, Orlando ^a   Miszputen, Sender Jankiel ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

inflammatory bowel disease; infliximab, pregnancy

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE; INFLIXIMAB; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACIAL REDNESS; FEMALE; GESTATIONAL AGE; HUMAN; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN REDNESS; TACHYCARDIA; TOXIC MEGACOLON;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957564919     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328329543a     Document Type: Article

References (49)

1. Hanan IM. Inflammatory bowel disease in the pregnant woman. Compr Ther 1993;19:91-95.
2. Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006;101:1539-1545.
3. Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, et al. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol 2007;22:542-549.
4. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004;270:79-85. (Pubitemid 39208317)
5. Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 2003;52:159-161.
6. Beniada A, Benoist G, Maurel J, Dreyfus M. Inflammatory bowel disease in pregnancy: report of 76 cases and review of the literature. J Gynecol Obstet Biol Reprod (Paris) 2005;34:581-588.
7. Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 2007;26:513-533.
8. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830-837.
9. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease - a population-based cohort study. Am J Obstet Gynecol 1997;177:942-946.
10. Calderwood AH, Kane SV. IBD and pregnancy. Med Gen Med 2004;6:14. www.pubmedcentral.nih.gov
11. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980;21:469-474.
12. Subhani JM, Hamiliton MI. Review article: the management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998;12:1039-1053.
13. Cappell MS, Colon VJ, Sidhom OA. A study of 10 medical centres of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996;41:2353-2361.
14. Frank B. Endoscopy during pregnancy. In: Karlsadt RG, Croitoru R, editors. Gastrointestinal disorders during pregnancy. American College of Gastroenterology. Arlington, VA: Elsevier; 1994. pp. 24-29.
15. Siddiqui U, Denise Proctor D. Flexible sigmoidoscopy and colonoscopy during pregnancy. Gastrointest endosc Clin N Am 2006;16:59-69.
16. Järnerot G, Into-Malberg MB, Esbjörner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981;16:693-697.
17. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984;25:52-56.
18. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-76.
19. Craxi A, Pagliarello F. Possible embryotoxicity of sulphasalazine. Arch Intern Med 1980;140:1674.
20. Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 1988;318:1128-1129.
21. Newman NM, Correy JF. Possible teratogenicity of sulphasalazine. Med J Aust 1983;1:528-529.
22. Jarnerot G, Andersen S, Esbjorner E, Sandstrom B, Brodersen R. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981;16:1049-1055.
23. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy end lactation. Acta Paediatr Scand 1987;76:137-142.
24. Colombel JF, Brabant G, Gubler MC, Locquet A, Comes MC, Dehennault M, Delcroix M. Renal insuficiency in infant: sideeffect of prenatal exposure to mesalazine? Lancet 1994;344:620-621.
25. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalazine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23-28. (Pubitemid 28020950)
26. Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with IBD treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998;12:1101-1108.
27. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-438.
28. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the foetus of medications used in pregnant inflammatory bowel disease patients. Am J Gastroenterol 2004;99:656-661.
29. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004;18:93-101.
30. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by human placenta. Am J Obstet Gynecol 1977;127:264-267.
31. Dancis J, Jancen V, Levitz M. Placental transfer of steroids: effect of binding to serum albumin and to placenta. Am J Physiol 1980;238:208-213.
32. Padbury JF, Ervin MG, Polk DH. Extrapulmonary effects of antenatally administered steroids. J Pediatr 1996;128:167-172.
33. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) in pregnancy. Am J Obstet Gynecol 1967;97:708-710.
34. Kucerova M, Kocandrle V, Matousek V, Polikova Z, Reneltova I. Chromosomal aberrations and sister-chromatid exchanges (SCEs) in patients undergoing long-term Imuran therapy. Mutat Res 1982;94:501-509.
35. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051-1055.
36. Milunsky A, Graef JW, Gaynor MF. Methotrexate induced congenital malformations. J Pediatr 1968;72:790-795.
37. Powell HR, Ekert H. Methotrexate-induced congenital malformations. Med J Aust 1971;2:1076-1077.
38. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
39. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-529.
40. Berkovitch M, Pastuszak A, Gazarian M, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994;84:535-538.
41. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbe A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55(Suppl 1):i36-i58.
42. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001;96:2274-2275.
43. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890.
44. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-738.
45. Vasilauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-1258.
46. Roux CH, Brocq O, Breuli V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumor necrosis factor (TNF)-alpha therapy. Rheumatology 2007;46:695-698.
47. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in woman receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-2392.
48. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in woman with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-246.
49. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004;15:237-241.